Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

LEXINGTON, Mass.--(BUSINESS WIRE)--Novo Nordisk today announced that the acquisition of Dicerna, announced on 18 November 2021, has been completed.

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Novo Nordisk AS ( NVO , Financial) is shelling out $3.3 billion to buy partner Dicerna Pharmaceuticals Inc. ( DRNA , Financial). That's $38.25 per share in cash, an 80% premium to the $21.28 closing price of Dicerna on Wednesday, Nov. 17, and the third-highest premium in a deal for a publicly-traded biotech this year, according to BioPharma Dive's database.

Shares of RNAi Drug Companies Pop After Novo Lays Out $3.3 Billion for Dicerna

NEW YORK, Nov. 22, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Dicerna Pharmaceuticals, Inc. ("DRNA" or the "Company") (DRNA) relating to its proposed acquisition by Novo Nordisk. Under the terms of the agreement, DRNA shareholders will receive $38.25 in cash per share they own.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Dicerna Pharmaceuticals, Inc. - DRNA

Novo Nordisk

Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.

Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion

NEW YORK, Nov. 18, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company") (NASDAQ: DRNA) in connection with the proposed acquisition of the Company by Novo Nordisk. Under the terms of the merger agreement, the Company's shareholders will receive $38.25 per share in cash for each share of Dicerna common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.

New York, New York--(Newsfile Corp. - November 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company") (NASDAQ: DRNA) stock prior to November 18, 2021.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Dicerna to Novo Nordisk ("Novo). Under the terms of th

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo Nordisk

Dicerna Pharmaceuticals (Nasdaq: DRNA) is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about $3.3 billion, shares in cash of $38.25 each.  Both the Board of Directors of Novo Nordisk and Dicerna Pharmaceuticals unanimously approved this transaction.

Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%

Rivian Automotive

Find out what took two stocks listed on the Nasdaq in different directions on Thursday.

Rivian Plunges, but This Under-the-Radar Nasdaq Stock Is Soaring

A juicy buyout offer from Novo Nordisk is giving Dicerna shareholders a big reason to cheer.

Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today

MILWAUKEE, Nov. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating Dicerna (Nasdaq: DRNA), for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk.  Click here to learn how to join the action: https://www.ademilaw.com/case/dicerna-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Dicerna Pharmaceuticals, Inc. has obtained a Fair Price in its going private transaction with Novo Nordisk

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share in cash is fair to Dicerna shareholders. Halper Sadeh encourages Dicerna shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether D

Dicerna Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dicerna Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – DRNA

Dicerna Pharmaceuticals (DRNA) stock is surging higher on Thursday following news of a massive $3.3 billion deal with Novo Nordisk. The post DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today appeared first on InvestorPlace.

DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today

Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to Dicerna's closing price on November 17, 2021. "The acquisition of Dicerna accelerates Novo Nordisk's research within RNAi and expands the usage of the RNAi technology," said Marcus Schindler, the CSO of Novo Nordisk.

Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA)  announced it entered into a definitive agreement with Novo Nordisk A/S (NYSE: NVO) under which Novo Nordisk will acquire Dicerna. This is why.

Why Novo Nordisk (NVO) Is Buying Dicerna Pharmaceuticals (DRNA) For $3.3 Billion

(Reuters) -Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.

Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion

Novo Nordisk NVO, +0.37% NOVO.B, +0.69% said it's buying Dicerna Pharmaceuticals DRNA, -0.09% for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28.

Novo Nordisk strikes $3.3 billion to buy research partner Dicerna Pharmaceuticals

LEXINGTON, Mass.--(BUSINESS WIRE)--DRNA announces definitive agreement with Novo Nordisk to be acquired for $38.25 per share in cash, which represents total equity value of $3.3 billion

Novo Nordisk to Acquire Dicerna

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announces Lilly has declared proof of principle for first two targets in the companies' exclusive relationship in neurodegeneration and pain.

Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna presented results from its Phase 1 trial of belcesiran, in development for the treatment of AATLD, at AASLD.

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q3 2021 Results - Earnings Call Transcript

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of 46.34% and 7.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Tops Revenue Estimates

Dicerna Pharmaceuticals (NASDAQ:DRNA) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Dicerna Pharmaceuticals: Q3 Earnings Insights

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announces Q3FY21 financial results and provides business update.

Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced results of the PHYOX™2 pivotal clinical trial of nedosiran in a late-breaker poster presentation at the ASN Kidney Week 2021.

News for Dicerna Pharmaceuticals Stock (DRNA)